TABLE 1.
In vitro activity of tetracyclines, macrolides, quinolones, and rifampin against a chloroquine-susceptible clone, 3D7, and chloroquine-resistant strains, W2, Palo Alto, FCR3, and Bres1
| Antibiotic | Mean IC50 (μM) (95% confidence interval)a against:
|
||||
|---|---|---|---|---|---|
| 3D7 | W2 | FCR3 | Bres1 | Palo Alto | |
| Doxycycline | 9.7 (8.1–11.5) | 7.7 (7.1–8.4) | 12.4 (10.9–14.0) | 14.9 (11.5–19.3) | 11.2 (10.0–12.5) |
| Tetracycline | 42.7 (36.3–50.2) | 33.8 (26.4–43.3) | 62.2 (43.8–88.5) | 88.9 (60.3–131.1) | 88.1 (66.9–116.0) |
| Minocycline | 10.2 (8.5–12.3) | 16.0 (11.8–21.6) | 15.6 (12.4–18.8) | 17.0 (14.3–20.3) | 12.3 (9.6–15.8) |
| Oxytetracycline | 34.4 (19.5–60.7) | 46.0 (44.2–47.9) | 54.5 (50.6–58.4) | 67.5 (63.3–71.9) | 47.9 (44.1–51.9) |
| Rolitetracycline | 208.0 (172.8–250.2) | 45.5 (35.2–58.8) | 155.9 (137.8–174.0) | 117.5 (110.3–125.2) | 203.2 (168.9–244.5) |
| Norfloxacin | 55.3 (39.1–78.3) | 74.6 (70.7–78.8) | 54.1 (38.5–75.9) | 58.6 (40.7–84.5) | 75.0 (66.1–85.1) |
| Ofloxacin | 152.1 (109.4–211.4) | 112.5 (105.1–120.3) | 113.8 (103.0–125.6) | 158.1 (152.5–163.9) | 195.0 (152.8–248.8) |
| Rifampin | 3.2 (2.8–3.7) | 1.3 (1.0–1.5) | 1.7 (1.5–2.9) | 1.9 (1.4–2.6) | 2.1 (1.7–2.7) |
| Erythromycin | >250 | 39.4 (27.9–55.5) | 18.0 (14.9–21.6) | 24.3 (21.9–26.9) | 17.5 (12.8–24.0) |
| Spiramycin | 69.0b (53.1–89.7) | 20.9b (18.6–23.5) | 19.0b (15.9–22.7) | 13.7b (9.2–20.4) | 20.8b (17.0–25.5) |
| Roxithromycin | >250 | 18.6 (14.6–23.6) | 12.8 (8.1–20.2) | 13.3 (8.2–21.7) | 6.8 (4.7–9.9) |
a
Values are the geometric mean IC50 of 5 to 10 assays.
b
Units per milliliter.